• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在医疗机构相关性艰难梭菌感染爆发期间,优先使用万古霉素治疗时,并未发现万古霉素耐药肠球菌定植增加。

Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.

机构信息

Jewish General Hospital, Montreal, Quebec, Canada.

出版信息

Infect Control Hosp Epidemiol. 2010 Jul;31(7):710-5. doi: 10.1086/653613.

DOI:10.1086/653613
PMID:20518636
Abstract

OBJECTIVE

To assess whether use of oral vancomycin for treatment during an outbreak of Clostridium difficile infection (CDI) was associated with increased rates of colonization with vancomycin-resistant enterococci (VRE).

DESIGN

A retrospective analysis of hospital databases.

SETTING

The Jewish General Hospital in Montreal, Quebec, Canada.

METHODS

We collected data regarding VRE colonization and CDI from November 1, 2000, through September 30, 2007, during which policies of preferential oral metronidazole or vancomycin treatment were implemented to control an outbreak of CDI. Four periods were considered: period 1, the preoutbreak period when metronidazole was used; period 2, the CDI outbreak period when metronidazole was used; period 3, the postoutbreak period when vancomycin was used; and period 4, the postoutbreak period when metronidazole was used.

RESULTS

A total of 2,412 cases of CDI and 425 cases of VRE colonization were identified. The rate of CDI increased significantly during period 2 and decreased to preoutbreak levels during period 3. The rate of VRE also increased during period 2 and decreased during the first 18 months of period 3. A clonal outbreak of cases of VRE (VanA) colonization was observed toward the end of period 3 and into period 4. Excluding the period of the clonal outbreak, there was a strong correlation between the number of cases of CDI and VRE colonization (r=0.736; P=.001) and a negative association between VRE colonization and vancomycin use (r=-0.765; P=.04).

CONCLUSIONS

Increased vancomycin use was not associated with an increase in VRE colonization over a 2-year period. Restriction of vancomycin use during CDI outbreaks because of the fear of increasing VRE colonization may not be warranted.

摘要

目的

评估在艰难梭菌感染(CDI)爆发期间使用口服万古霉素治疗是否与增加耐万古霉素肠球菌(VRE)定植率相关。

设计

医院数据库的回顾性分析。

地点

加拿大魁北克省蒙特利尔的犹太总医院。

方法

我们收集了 2000 年 11 月 1 日至 2007 年 9 月 30 日期间有关 VRE 定植和 CDI 的数据,在此期间实施了优先使用口服甲硝唑或万古霉素的治疗策略以控制 CDI 的爆发。考虑了四个时期:时期 1,爆发前使用甲硝唑的时期;时期 2,使用甲硝唑的 CDI 爆发时期;时期 3,使用万古霉素的爆发后时期;以及时期 4,使用甲硝唑的爆发后时期。

结果

共发现 2412 例 CDI 和 425 例 VRE 定植病例。在时期 2 期间,CDI 的发生率显著增加,并在时期 3 期间降低至爆发前水平。VRE 的发生率也在时期 2 期间增加,并在时期 3 的前 18 个月期间下降。在时期 3 接近尾声和时期 4 期间观察到 VRE(VanA)定植的克隆爆发。排除克隆爆发期间,CDI 和 VRE 定植的病例数之间存在很强的相关性(r=0.736;P=.001),并且 VRE 定植与万古霉素使用之间存在负相关(r=-0.765;P=.04)。

结论

在 2 年期间,增加万古霉素的使用与 VRE 定植的增加无关。由于担心增加 VRE 定植而在 CDI 爆发期间限制万古霉素的使用可能没有必要。

相似文献

1
Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.在医疗机构相关性艰难梭菌感染爆发期间,优先使用万古霉素治疗时,并未发现万古霉素耐药肠球菌定植增加。
Infect Control Hosp Epidemiol. 2010 Jul;31(7):710-5. doi: 10.1086/653613.
2
Prevalence of colonization and infection with methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus and of Clostridium difficile infection in Canadian hospitals.加拿大医院耐甲氧西林金黄色葡萄球菌和万古霉素耐药肠球菌定植和感染以及艰难梭菌感染的流行情况。
Infect Control Hosp Epidemiol. 2013 Jul;34(7):687-93. doi: 10.1086/670998. Epub 2013 May 13.
3
Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease.接受口服甲硝唑或口服万古霉素治疗艰难梭菌相关性疾病的患者皮肤及环境中耐万古霉素肠球菌的污染情况
Infect Control Hosp Epidemiol. 2009 Jan;30(1):13-7. doi: 10.1086/592710.
4
Multipronged intervention strategy to control an outbreak of Clostridium difficile infection (CDI) and its impact on the rates of CDI from 2002 to 2007.2002年至2007年期间,采用多管齐下的干预策略控制艰难梭菌感染(CDI)疫情及其对CDI发病率的影响。
Infect Control Hosp Epidemiol. 2009 Feb;30(2):156-62. doi: 10.1086/593955.
5
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.在艰难梭菌相关性疾病的治疗过程中,口服甲硝唑和口服万古霉素均会促使耐万古霉素肠球菌持续过度生长。
Antimicrob Agents Chemother. 2008 Jul;52(7):2403-6. doi: 10.1128/AAC.00090-08. Epub 2008 Apr 28.
6
Clostridium difficile and vancomycin-resistant enterococcus: the new nosocomial alliance.艰难梭菌与耐万古霉素肠球菌:新的医院内联盟。
Am J Gastroenterol. 2000 Dec;95(12):3513-5. doi: 10.1111/j.1572-0241.2000.03291.x.
7
Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?万古霉素用于治疗艰难梭菌感染:这种昂贵的药物究竟对谁有神奇疗效?
Clin Infect Dis. 2008 May 15;46(10):1493-8. doi: 10.1086/587656.
8
Treatment of Clostridium difficile infection in a French university hospital.法国一家大学医院艰难梭菌感染的治疗
Scand J Gastroenterol. 2015;50(10):1253-60. doi: 10.3109/00365521.2015.1033746. Epub 2015 Apr 15.
9
Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin.韩国一家三级医疗中心医院耐万古霉素肠球菌感染的突然增加:口服万古霉素使用增加的可能后果
J Infect Chemother. 2003 Mar;9(1):62-7; discussion 104-5. doi: 10.1007/s10156-002-0215-5.
10
Increase in use of vancomycin for Clostridium difficile infection in US hospitals.美国医院中用于艰难梭菌感染的万古霉素使用量增加。
Infect Control Hosp Epidemiol. 2010 Aug;31(8):867-8. doi: 10.1086/655442.

引用本文的文献

1
When is an outbreak an outbreak? Using literature and discharge data to define Clostridioides difficile incidence changes referred to as outbreaks.何时爆发疫情?通过文献和出院数据来定义被称为疫情的艰难梭菌感染发生率变化。
J Hosp Infect. 2020 Jun;105(2):225-231. doi: 10.1016/j.jhin.2020.03.019. Epub 2020 Mar 20.
2
Clostridium Difficile Colitis in Trauma Patients - a Global Step by Step Review.创伤患者中的艰难梭菌性结肠炎——全球逐步综述
Maedica (Bucur). 2015 Jun;10(2):163-169.
3
[Clostridium difficile infections in geriatric patients].
老年患者艰难梭菌感染
Z Gerontol Geriatr. 2016 Dec;49(8):743-761. doi: 10.1007/s00391-016-1143-9. Epub 2016 Oct 26.
4
Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.万古霉素二级预防在预防艰难梭菌反复感染中的疗效
Am J Gastroenterol. 2016 Dec;111(12):1834-1840. doi: 10.1038/ajg.2016.417. Epub 2016 Sep 13.
5
Rational Therapy of Clostridium difficile Infections.艰难梭菌感染的合理治疗
Viszeralmedizin. 2014 Oct;30(5):304-9. doi: 10.1159/000366302.
6
SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model.SMT19969 作为艰难梭菌感染的治疗药物:使用传统药敏试验和体外肠道模型对抗菌活性的评估
J Antimicrob Chemother. 2015 Jan;70(1):182-9. doi: 10.1093/jac/dku324. Epub 2014 Sep 3.
7
Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center.艰难梭菌相关性疾病:在一家三级医疗中心遵循当前指南的情况。
World J Gastroenterol. 2013 Dec 14;19(46):8647-51. doi: 10.3748/wjg.v19.i46.8647.
8
In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.体外研究 CB-183,315、万古霉素和甲硝唑对 556 株艰难梭菌、445 株其他肠道厌氧菌和 56 株肠杆菌科细菌的活性。
Antimicrob Agents Chemother. 2012 Mar;56(3):1613-5. doi: 10.1128/AAC.05655-11. Epub 2011 Dec 19.
9
Reducing the risk of severe complications among patients with Clostridium difficile infection.降低艰难梭菌感染患者发生严重并发症的风险。
Can J Gastroenterol. 2011 Jul;25(7):368-72. doi: 10.1155/2011/153020.
10
Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization.艰难梭菌感染复发的危险因素:万古霉素耐药肠球菌定植的影响。
J Korean Med Sci. 2011 Jul;26(7):859-64. doi: 10.3346/jkms.2011.26.7.859. Epub 2011 Jun 20.